23 May 2013 - Diagnostic test kits company Corgenix Medical Corporation (OTC Markets:CONX) revealed on Wednesday the launch of a new partnership with Eli Lilly and Company (NYSE: LLY) to develop diagnostic technology in support of a Lilly oncology pipeline programme.

As part of the agreement, the partnership will collaborate to further advance this proprietary diagnostic technology originally developed by Lilly.

The companies have not disclosed the financial terms of the agreement.

This collaboration is reportedly part of Corgenix' recent expansion of its Contract Services Business Unit for contract product development, technology application and manufacturing for the healthcare and biotechnology industries.